Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450249 | 0.88 | ADORA2A (0.63) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL15484578 | 0.85 | ADORA2A (0.66) | ADORA2AADORA1ADORA3ALDH1A1KMT2A | |
| SCHEMBL1449509 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA3NPC1ALDH1A1 | |
| SCHEMBL5508760 | 0.84 | ADORA2A (0.82) | ADORA2AADORA1ALDH1A1KMT2A | |
| SCHEMBL1449335 | 0.84 | ADORA2A (0.81) | ADORA2AADORA1ADORA3NPC1ALDH1A1 | |
| SCHEMBL1449367 | 0.83 | ADORA2A (0.83) | ADORA2AADORA1NPC1ALDH1A1RAB9A | |
| Cyclopropane SCHEMBL15484716 | 0.82 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| Cyclohexane SCHEMBL15484642 | 0.82 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1449376 | 0.81 | ADORA2A (0.77) | ADORA2AADORA1NPC1ALDH1A1RAB9A | |
| SCHEMBL1449994 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885ADORA3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.